Cirrhosis is a leading cause of death worldwide, often with septic shock as the terminal event. Relative adrenal insufficiency shares similar features of distributive hyperdynamic shock with both cirrhosis and sepsis and increasingly has been reported to coexist with both conditions. The effect of low-dose hydrocortisone therapy on survival of critically ill patients in general with septic shock remains controversial, with conflicting results from randomized controlled trials and meta-analyses. The effect of hydrocortisone therapy on mortality among patients with cirrhosis, who are known to be a group at high risk for relative adrenal insufficiency, has not been studied and hence was the objective of our study.

Methods

Setting

The study was conducted in a 900-bed, tertiary care academic hospital. Patients with cirrhosis who present with septic shock are admitted to the 21-bed medical–surgical intensive care unit (ICU), which is run as a closed unit around the clock by in-house certified specialists in critical care. A multidisciplinary team of hepatologists, gastroenterologists and transplant surgeons coordinate the care of patients who have cirrhosis with the admitting intensivists.

Study design

Consecutive patients aged 18 years or older with liver cirrhosis who presented with septic shock were eligible within 72 hours of the onset of hypotension for this randomized double-blind placebo-controlled trial. The study was approved by the Institutional Review Board of King Abdulaziz Medical City, registered at the Current Controlled Trials registry and conducted from April 2004 to October 2007. Definitions and exclusion criteria are described in Appendix 1, available at www.cmaj.ca/cgi/content/full/cmaj.090707/DC1.

Randomization and interventions

After obtaining consent, enrolled patients underwent a corticotropin stimulation test and randomization. Blood samples were drawn for baseline serum levels of cortisol, corticotropin, interleukin-6 and tumour necrosis factor-α.
followed by administration of 250 µg of intravenous corticosterone (Synacthen, Alliance Pharmaceuticals, United Kingdom). After 60 minutes, another blood sample was obtained for serum cortisol level. Laboratory personnel were blinded to the treatment allocation. The results of the corticosterone stimulation test and of tests for interleukin-6 and tumour necrosis factor-α were blinded to both the treating physicians and study investigators.

Randomization was performed by a central pharmacy using consecutive sealed envelopes and based on computer-generated random allocation in blocks to one of two arms in which participants received intravenous bolus injections every six hours of 5 mL of normal saline containing 50 µg of hydrocortisone or normal saline (placebo). The two interventions were indistinguishable. Patients as well as medical, nursing and clinical pharmacist staff remained blinded to the allocated therapy throughout the study. The full dose of the study drug was continued until shock resolution, which was defined as blood pressure stability (i.e., mean arterial pressure > 65 mm Hg) without vasopressors for 24 hours. The six-hourly dose was then reduced by 1 mL every two days without discontinuation. If the mean arterial pressure remained above 65 mm Hg for more than 24 hours without vasopressors after complete cessation of the study drug, this was considered an end point for the intervention. However, if hypotension recurred during weaning, the dose was increased to full dosage again. If hypotension recurred after 24 hours of complete cessation of the study drug, the decision to use hydrocortisone or not as open label was left to the discretion of the treating physician.

Management in the ICU and cointerventions
All patients received hemodynamic monitoring and management, laboratory testing, antimicrobial therapy and stress-ulcer prophylaxis using a standardized protocol. Hemodynamic support followed the early goal-directed therapy protocol of Rivers and colleagues.21 Norepinephrine was the vasopressor of choice, and meropenem was the empiric antibiotic of choice unless indicated otherwise by cultures and clinical setting. All patients received histamine H2-receptor antagonists or proton pump inhibitors for stress-ulcer prophylaxis.

Outcomes
The primary outcome was 28-day all-cause mortality. Secondary outcomes included ICU-specific and hospital-specific mortality, mean arterial pressure, vasopressor doses, shock reversal, vasopressor-free days, mechanical ventilation-free days and renal replacement-free days (during the first 28 study days). We documented length of stay in ICU for ICU survivors and length of stay in hospital for hospital survivors. We documented the occurrence of the following potentially intervention-related side effects: severe hyperglycemia (> 10 mmol/L or > 180 mg/dL), shock relapse (i.e., hypotension recurrence during weaning or within seven days of total discontinuation of the study drug), arrhythmia, gastrointestinal bleeding, bacteremia and ventilator-associated pneumonia (as defined by the National Nosocomial Infections Surveillance System).22

**Cortisol, corticotropin and cytokine assays**
Cortisol was measured by an ARCHITECT analyzer (Abbott, Chicago, USA) using a chemiluminescent immunoassay. Corticotropin was measured using the autochemiluminescence system IMMULITE 2000 (Siemens Medical Solutions Diagnostics, New York, USA). Relative adrenal insufficiency was defined as a cortisol increase of less than 250 nmol/L or 9 µg/dL, from baseline after corticosterone stimulation.13 Samples for tumour necrosis factor-α and interleukin-6 were obtained on days one, three and seven, stored at −80°C and assayed using a solid-phase chemiluminescent enzyme immunoassay (Immulite, EURO/DPC Ltd., Gwynedd, UK) according to the manufacturer's specifications. The lowest detectable limit for interleukin-6 was 5 pg/mL, and for tumour necrosis factor-α, it was 1.7 pg/mL.

**Statistical analysis**
Statistical analyses were performed on an intention-to-treat basis. Based on an estimated baseline 28-day mortality of 90% and an estimated absolute risk reduction of 20%, 75 patients were required in each group using a two-sided type I error of 5% and a power of 80%. Stratified analyses were performed for several variables and were tested for interaction. Detailed descriptions of sample size calculation and statistical analyses, as well as study protocol, are available in Appendices 1 and 2 at www.cmaj.ca/cgi/content/full/cmaj.090707/DC1. A post-hoc futility analysis was carried out to calculate the conditional power of the study under the following three alternative assumptions: first, that the treatment effect size expected in future data would be the same as that in the original study design; second, that it would be the same as the trend in the data thus far; and third, that it would be zero (i.e., that the null hypothesis is true).23

![Figure 1: Flow of patients through the trial.](image-url)
Results

Study description

Of 140 patients screened, 75 were enrolled and randomly allocated (Figure 1). Sixty patients (80%) were enrolled within 24 hours after the onset of shock and 71 (95%) within 48 hours. For one patient, blinding was opened at the request of the primary physician, but the allocated therapy (placebo) was continued as planned per study protocol. The investigators performed a planned interim analysis after randomly allocating 75 patients drawn after randomly allocating 75 patients and found a trend toward excess 28-day mortality with hydrocortisone therapy compared with placebo (33 [85%] v. 26 [72%]; relative risk [RR] 1.17, 95% confidence interval [CI] 0.92–1.49, p = 0.19). The investigators stopped the trial for futility because the 95% CI for the RR for the primary outcome excluded the anticipated RR of 0.78 with hydrocortisone. Post-hoc futility analyses yielded very low conditional powers of 3.4% for the first assumption described earlier, 0.00% for the second and 0.01% for the third. These results indicate that it is highly unlikely that a significant treatment benefit would be evident even if the trial were completed to the targeted sample size.

Patient characteristics

Baseline characteristics, including use of etomidate, were similar in the two groups (Table 1). Cortisol levels were not different at baseline and increased modestly after corticotropin stimulation to similar levels in the two groups. Overall, 76% of patients had a cortisol increase of less than 250 nmol/L (9 µg/dL) from baseline (i.e., “nonresponders”), with similar proportions in the two groups.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Hydrocortisone n = 39</th>
<th>Placebo n = 36</th>
<th>Characteristic</th>
<th>Hydrocortisone n = 39</th>
<th>Placebo n = 36</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory findings, median (IQR)</td>
<td></td>
<td></td>
<td>Laboratory findings, median (IQR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albumin, g/L</td>
<td>30.0 (8.0)</td>
<td>34.5 (12.5)</td>
<td>Almminin, g/L</td>
<td>30.0 (8.0)</td>
<td>34.5 (12.5)</td>
</tr>
<tr>
<td>Platelet count, ×10^9/L</td>
<td>73.0 (57.0)</td>
<td>94.5 (71.5)</td>
<td>Lactic acid, mmol/L†</td>
<td>2.8 (3.2)</td>
<td>3.0 (3.4)</td>
</tr>
<tr>
<td>Hemoglobin, g/L</td>
<td>82.0 (25.0)</td>
<td>83.5 (18.0)</td>
<td>Shock duration before inclusion, h</td>
<td>5.0 (21.0)</td>
<td>11.0 (21.0)</td>
</tr>
<tr>
<td>Leukocyte count, ×10^9/L</td>
<td>10.3 (12.1)</td>
<td>11.3 (10.9)</td>
<td>Shock duration before first dose of study drug, h</td>
<td>10.0 (21.0)</td>
<td>14.2 (15.9)</td>
</tr>
<tr>
<td>Hemodynamic parameters, median (IQR)</td>
<td></td>
<td></td>
<td>Norepinephrine dose at inclusion, µg/kg per min</td>
<td>0.30 (0.54)</td>
<td>0.17 (0.46)</td>
</tr>
<tr>
<td>PaO2/FIO2 ratio, median (IQR)</td>
<td>180.0 (173.0)</td>
<td>236.5 (182.0)</td>
<td>Respiratory parameters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td></td>
<td></td>
<td>Patients needing mechanical ventilation, no. (%)</td>
<td>34 (87)</td>
<td>28 (78)</td>
</tr>
<tr>
<td>FIO2, median (IQR)</td>
<td>0.4 (0.4)</td>
<td>0.3 (0.3)</td>
<td>PEEP, cm H2O, median (IQR)</td>
<td>8.0 (7.0)</td>
<td>5.0 (5.0)</td>
</tr>
<tr>
<td>Tidal volume, mL, median (IQR)</td>
<td>500.0 (117.5)</td>
<td>500.0 (100.0)</td>
<td>Duration of study medication, d, mean (SD)</td>
<td>6.6 (4.2)</td>
<td>8.8 (5.5)</td>
</tr>
<tr>
<td>Adrenal function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline cortisol, nmol/L, median (IQR)†</td>
<td>483.5 (435.0)‡</td>
<td>406.0 (428.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticosterone, µg/dL, median (IQR)†</td>
<td>17.1 (30.9)⁺</td>
<td>25.8 (35.8)⁺</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60-min cortisol, nmol/L, median (IQR)‡</td>
<td>594.0 (470.0)$</td>
<td>529.0 (334.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in cortisol, nmol/L, median (IQR)†</td>
<td>103.0 (208.0)</td>
<td>70.0 (167.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonresponders, no. (%)</td>
<td>25 (76)</td>
<td>26 (79)</td>
<td>Responders, no. (%)</td>
<td>8 (24)</td>
<td>7 (21)</td>
</tr>
</tbody>
</table>

Note: APACHE II = Acute Physiology and Chronic Health Evaluation II; INR = international normalized ratio; IQR = interquartile range; PaO2:FIO2 ratio = ratio of partial pressure of oxygen to fraction of inspired oxygen; PEEP = positive expiratory end pressure; SD = standard deviation; SOFA = sequential organ failure assessment.

*Total of values may exceed 100% because some patients had more than one source of infection.
**To convert bilirubin to mg/dL, divide value by 17.1. To convert ammonia to µg/dL, divide value by 0.587. To convert lactic acid to mg/dL, divide value by 0.111. To convert cortisol to µg/dL, divide value by 27.59. To convert corticosterone to µmol/L, multiply value by 0.22.
†Missing one value (sample not withdrawn).
‡Missing six values (samples not withdrawn).
§Missing three values (samples not withdrawn).
ICU and cointerventions

Clinical parameters, including those related to fluid status and ventilatory pressures, and cointerventions, including transfusion requirements, were similar in the two groups (Table 2).

Mortality

There was no significant difference between the hydrocortisone and placebo groups in 28-day mortality (33 [85%] v. 26 [72%], RR 1.17, 95% CI 0.92–1.49, p = 0.19) or in ICU or hospital mortality (Table 3). Kaplan–Meier curves for survival at 28 days (Figure 2) also showed no significant difference (p = 0.50). Moreover, there was no significant interaction between response to corticotropin and assigned treatment with respect to 28-day mortality (p = 0.39).

Hemodynamic response

Hydrocortisone was associated with significant improvement in mean arterial pressure and with reduction in norepinephrine doses (Appendix 3, available at www.cmaj.ca/cgi/content/full/cmaj.090707/DC1) and an increase in shock reversal compared with placebo (24 [62%] v. 14 [39%], RR 1.58, 95% CI 1.08–2.55, p = 0.05). However, during and after tapering of the study drug, shock relapsed more often in the hydrocortisone group (13 [34%] v. 5 [14%], RR 2.58, 95% CI 1.04–6.45, p = 0.03). When stratified by the response to corticotropin, hemodynamic improvement was observed in nonresponders and not in responders (Appendix 3, panels C, D, E and F, available at www.cmaj.ca/cgi/content/full/cmaj.090707/DC1).

Other outcomes

There was no difference between the two groups in mechanical ventilation-free days, renal replacement therapy-free days, length of stay in ICU or length of stay in hospital (Table 3). Hydrocortisone was associated with higher rates of severe hyperglycemia and with a significant increase in the risk of gastrointestinal bleeding (RR 3.00, 95% CI 1.08–8.36).

Stratified analyses

With respect to 28-day mortality, there was no significant interaction between the assigned treatment and use of etomidate, duration of shock before randomization, duration of treatment with the study drug, Acute Physiology and Chronic Health Evaluation II score, or achievement of hemodynamic targets.

Cytokine levels

There was progressive reduction in the levels of interleukin-6 and tumour necrosis factor-α in the hydrocortisone and placebo groups. A significant difference in these levels between the hydrocortisone and placebo groups was seen only for tumour necrosis factor-α and only at day seven (15.6 ± 13.6 pg/ml v. 25.9 ± 18.0 pg/mL, p = 0.03).

Interpretation

Relative adrenal insufficiency was very common among patients with cirrhosis presenting with septic shock. Hydrocor-
tisone therapy resulted in a significant hemodynamic improvement, especially in nonresponders to corticotropicin. Despite these initial favourable hemodynamic effects, hydrocortisone therapy did not reduce mortality and was associated with an increase in shock relapse and gastrointestinal bleeding.

Corticosteroid therapy in septic shock has fallen in and out of favour over the last few decades.25,26 Annane and colleagues11 reported a significant reduction in mortality with hydrocortisone therapy among patients with septic shock — a finding that led to the recommendation of hydrocortisone as a standard therapy in the Surviving Sepsis Campaign.27 Similar results have been reported in other studies14-16 and a meta-analysis.14 However, the results of the study by Annane and colleagues were considered borderline because they were achieved only after statistical adjustment18 and because crude in-hospital mortality was higher among responders to corticotropin who received hydrocortisone. More recently, the Corticosteroid Therapy of Septic Shock (CORTICUS) study showed that corticosteroids had no effect on 28-day mortality, even among nonresponders.17

Relative adrenal insufficiency has recently been described in 62%—80% of heterogeneous groups of patients with liver disease.11,12,29-30 Our study shows a prevalence of relative adrenal insufficiency reaching 76% in a homogenous group of patients with cirrhosis presenting with septic shock. Several potential mechanisms have been postulated, including adrenal exhaustion,31 inhibition of cortisol synthesis by tumour necrosis factor-α32 and, less likely, adrenal hemorrhage.29

Despite this high prevalence of relative adrenal insufficiency, our study showed no survival benefit with hydrocortisone therapy, although hemodynamic parameters improved significantly. There are several potential explanations. First, it has been suggested that the benefit observed by Annane and colleagues but not in the CORTICUS study was related to the shorter randomization window (8 v. 72 hours). In our study, 80% of patients were enrolled within the first 24 hours after the onset of shock. Furthermore, we found no interaction between the assigned treatment and the duration of shock before randomization with respect to 28-day mortality.

Second, 33% of our patients had received etomidate, which is known to cause adrenal suppression.31 However, this proportion was not different in the CORTICUS study (26% of patients) or the study by Annane and colleagues (24% of patients). Furthermore, we found no interaction between the assigned treatment and etomidate use with respect to 28-day mortality.

### Table 3: Outcomes among patients with cirrhosis and sepsis receiving low-dose hydrocortisone

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Hydrocortisone n = 39</th>
<th>Placebo n = 36</th>
<th>Relative risk (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28-day mortality, no. (%)</td>
<td>33 (85)</td>
<td>26 (72)</td>
<td>1.17 (0.92 to 1.49)</td>
<td>0.19</td>
</tr>
<tr>
<td>ICU mortality, no. (%)</td>
<td>24 (62)</td>
<td>24 (67)</td>
<td>0.92 (0.66 to 1.30)</td>
<td>0.64</td>
</tr>
<tr>
<td>Hospital mortality, no. (%)</td>
<td>34 (87)</td>
<td>32 (89)</td>
<td>0.98 (0.83 to 1.16)</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>Hemodynamic response</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in norepinephrine infusion rate (day 2 – day 1), µg/kg per min, mean (SD)</td>
<td>–0.08 (0.22)</td>
<td>0.09 (0.28)</td>
<td>–0.17 (–0.28 to –0.05)*</td>
<td>0.005</td>
</tr>
<tr>
<td>Change in norepinephrine infusion rate (day 3 – day 1), µg/kg per min, mean (SD)</td>
<td>–0.16 (0.29)</td>
<td>0.11 (0.32)</td>
<td>–0.27 (–0.40 to –0.12)*</td>
<td>0.0006</td>
</tr>
<tr>
<td>Shock reversal, no. (%)</td>
<td>24 (62)</td>
<td>14 (39)</td>
<td>1.58 (0.91 to 2.55)</td>
<td>0.05</td>
</tr>
<tr>
<td>Vasopressor-free days, mean (SD)</td>
<td>6.8 (7.9)</td>
<td>5.6 (8.9)</td>
<td>1.2 (–2.7 to 5.1)*</td>
<td>0.54</td>
</tr>
<tr>
<td><strong>Other outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ventilation-free days, mean (SD)</td>
<td>6.7 (7.7)</td>
<td>8.1 (10.9)</td>
<td>–1.4 (–5.8 to 2.9)*</td>
<td>0.51</td>
</tr>
<tr>
<td>Renal replacement therapy-free days, mean (SD)</td>
<td>6.7 (7.8)</td>
<td>6.4 (10.6)</td>
<td>0.2 (–4.0 to 4.5)*</td>
<td>0.92</td>
</tr>
<tr>
<td>ICU length of stay for ICU survivors, d, mean (SD)</td>
<td>9.2 (6.4)</td>
<td>9.6 (6.0)</td>
<td>–0.4 (–5.4 to 4.5)*</td>
<td>0.86</td>
</tr>
<tr>
<td>Hospital length of stay for hospital survivors, d, mean (SD)</td>
<td>27.2 (12.8)</td>
<td>43.3 (34.0)</td>
<td>–16.1 (–54.5 to 22.4)*</td>
<td>0.90</td>
</tr>
<tr>
<td><strong>Complications</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shock relapse, no. (%)</td>
<td>14 (36)</td>
<td>5 (14)</td>
<td>2.46 (0.98 to 6.21)</td>
<td>0.03</td>
</tr>
<tr>
<td>Arrhythmia, no. (%)</td>
<td>10 (26)</td>
<td>6 (17)</td>
<td>1.54 (0.62 to 3.80)</td>
<td>0.34</td>
</tr>
<tr>
<td>Gastrointestinal bleeding, no. (%)</td>
<td>13 (33)</td>
<td>4 (11)</td>
<td>3.00 (1.08 to 8.36)</td>
<td>0.02</td>
</tr>
<tr>
<td>Hyperglycemia &gt; 10 mmol/L, no. (%)</td>
<td>34 (87)</td>
<td>25 (69)</td>
<td>1.26 (0.98 to 1.61)</td>
<td>0.06</td>
</tr>
<tr>
<td>Ventilator-associated pneumonia, no. (%)</td>
<td>8 (21)</td>
<td>3 (8)</td>
<td>2.46 (0.71 to 8.57)</td>
<td>0.14</td>
</tr>
<tr>
<td>ICU-acquired bacteremia, no (%)</td>
<td>14 (36)</td>
<td>15 (42)</td>
<td>0.86 (0.49 to 1.52)</td>
<td>0.61</td>
</tr>
<tr>
<td>Any major complication, no. (%)</td>
<td>25 (64)</td>
<td>14 (39)</td>
<td>1.65 (1.03 to 2.64)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Note: CI = confidence interval, ICU = intensive care unit, SD = standard deviation.
*Mean difference and 95% CI.
the use of aldosterone antagonists to treat ascites. Addition-
ally, the absorption of oral medications is unreliable in patients
with cirrhosis, and a daily hydrocortisone dose of 200 mg,
which was used in these trials, provides adequate mineralocor-
ticoid activity.17

Third, Annane and colleagues used fludrocortisone,
whereas the CORTICUS study did not. However, cirrhosis
is characterized by hyperaldosteronism,34 which is the basis
for the use of aldosterone antagonists to treat ascites.35 Additionally,
all the potential benefit. Sixth, the low-dose hydrocortisone
was tapered in some patients while vasopressors were still
required, these numbers may underestimate the hemodynamic
deterioration due to steroid tapering. The very high mortality
associated with relapse of shock may have mitigated any ben-
eficial effects of hydrocortisone. Why did shock recur after
tapering of hydrocortisone? It is possible that relative adrenal insuffi-
ciency is inherent in patients with cirrhosis and not a
temporary sepsis-related phenomenon, and as such, a longer
duration of therapy might be required. Alternatively, hydro-
cortisone therapy may have further suppressed the pituitary–
adrenal axis, and thus tapering precipitated an adrenal crisis.

Fourth, we observed a significant increase in shock relapse
after weaning hydrocortisone. This increase was surprising
because of the relatively slow eight-day tapering protocol for
hydrocortisone initiated 24 hours after hemodynamic stability
was achieved. This protocol contrasts with cessation of cortico-
steroids after seven days by Annane and colleagues and
tapering from day 5 to 11 in the CORTICUS study, regardless
of hemodynamic status. In the CORTICUS trial, shock
relapse was observed in 31% of the hydrocortisone group and
25% of the placebo group. However, since hydrocortisone
was tapered in some patients while vasopressors were still
required, these numbers may underestimate the hemodynamic
deterioration associated with steroid tapering. The very high mortality
associated with relapse of shock may have mitigated any ben-
eficial effects of hydrocortisone. Why did shock recur after
tapering of hydrocortisone? It is possible that relative adrenal insuffi-
ciency is inherent in patients with cirrhosis and not a
temporary sepsis-related phenomenon, and as such, a longer
duration of therapy might be required. Alternatively, hydro-
cortisone therapy may have further suppressed the pituitary–
adrenal axis, and thus tapering precipitated an adrenal crisis.

Fifth, use of low-dose (often called “stress–” or “physio-
logic-dose”) hydrocortisone is not free of adverse effects. We
observed a three-fold increase in gastrointestinal bleeding
with very high associated mortality, which may have counter-
acted any potential benefit. Sixth, the low-dose hydrocorti-
sone is not a simple hormone replacement therapy, but rather
has clear immunomodulatory effects, as shown by the reduct-
ion in pro-inflammatory cytokines, which may alter the
body’s ability to mount an “appropriate” pro-inflammatory
response and host defences. Seventh, relative adrenal insuffi-
ciency may be just a marker of illness. If so, hydrocortisone
therapy would expose patients only to adverse effects, such as
further adrenal suppression, gastrointestinal bleeding and
immunosuppression. Finally, patients with cirrhosis and sep-
sis may constitute a special group that differs in physiology
and severity from other ICU patients with sepsis and perhaps
in response to hydrocortisone therapy.

The use of a corticotropin stimulation test before hydro-
cortisone therapy has been debated. A meta-analysis showed
beneficial effects of steroid therapy in both responders and
nonresponders to corticotropin,19 and the Surviving Sepsis
Campaign considered the test “optional.”20 However, our
study does not support hydrocortisone therapy in cirrhosis
without a corticotropin stimulation test because of lack of
hemodynamic and survival benefits in responders.

The use of free rather than total serum cortisol levels has
been suggested for the diagnosis of relative adrenal insuffi-
ciency because of dissociation between the levels of the total
and the physiologically active free cortisol.21 However, recent
guidelines have not recommended the routine use of free cor-
tisol measurements because of lack of availability and lack of
an established normal range in critically ill patients.22

Weakens and limitations
Weakens of our study included the randomized double-blind
placebo-controlled design, intention-to-treat analysis, homoge-
nous population, inclusion of steroid-naive patients and stan-
dardized ICU management. In addition, our protocolized slow
tapering of the study drug after achieving predefined param-
ters of hemodynamic stability was more physiologically
appropriate than use of a predefined schedule with abrupt ces-
sation or tapering irrespective of hemodynamic status.

As a limitation, our study was a single-centre trial, which
may affect its generalizability. Issues related to the length of
our study’s randomization window and to the use of etomi-
date are addressed earlier in the article.

Conclusion
Relative adrenal insufficiency is common in patients with cir-
rhosis presenting with septic shock. Hydrocortisone therapy
was associated with hemodynamic improvement. However, it
did not reduce mortality and was associated with an increase
in shock relapse and gastrointestinal bleeding. Our results
suggest a need for further multicentre randomized controlled
trials, possibly using lower doses of hydrocortisone and for a
longer duration.

This article has been peer reviewed.

Competing interests: Abdulmajeed Al-Abulkareem is a member of the
board of directors and the international advisory panel of King Faisal Specialist
Hospital and Research Center, Riyadh, Saudi Arabia. Waleed Tamimi has
received a research grant from King Abdullah City for Science and Technology,
Riyadh, Saudi Arabia. Ousama Dabbagh has received research grants from Bristol
Myers Squibb and Pfizer, and has served on the speaker bureau of Sanofi-aventis.
No competing interests declared by the other authors.

Contributors: Yaseen Arabi, Abdulrahman Aljumah, Ousama Dabbagh,
Abdulmajeed Al-Abulkareem, Ali Hajeer and Waleed Tamimi were respon-
sible for the conception and design of the study. Yaseen Arabi, Abdulrahman Aljumah, Ousama Dabbagh, Ashraf Rishu, Abdulmajeed Al-Abdulkareem, Bandar Al Knawy, Ali Hajeer, Waleed Tamimi and Antoine Cheffan took part in the acquisition of data. Yaseen Arabi, Hani Tamimi and Ali Hajeer were responsible for analysis and interpretation of data. Yaseen Arabi, Hani Tamimi, Ashraf Rishu and Ali Hajeer were responsible for drafting the manuscript. Yaseen Arabi, Abdulrahman Aljumah, Ousama Dabbagh, Abdulmajeed Al-Abdulkareem, Bandar Al Knawy, Ali Hajeer, Antoine Cheffan and Waleed Tamimi were in charge of critical revision of the manuscript for important intellectual content. Yaseen Arabi and Hani Tamimi were responsible for statistical analysis. All of the authors approved the final version of the manuscript submitted for publication. Yaseen Arabi was the primary investigator, had full access to all of the data and takes responsibility for the integrity of the data and accuracy of the data analysis.

Acknowledgements: The authors acknowledge the following colleagues from King Abdulaziz Medical City for their participation in patient recruitment, in-services, screening for eligible patients and assistance in data collection: Dr. Abdullah A. Al-Shimemer, Intensive Care Department; Dr. Ibrahim Traif, Department of Hepatobiliary Sciences; Mr. Salim H. Kahoul RN, Intensive Care Department; Mrs. Ricette J. Britts RN, Intensive Care Department; Dr. Sofia J. Syed MBBS, Intensive Care Department.

Funding: This study was funded by King Abdulaziz City for Science and Technology (grant no. LG-9-12).

REFERENCES

Correspondence to: Dr. Yaseen M. Arabi, King Saud Bin, Abdulaziz University for Health Sciences, King Abdulaziz Medical City, PO Box 22490, Intensive Care Department, MC 1425, Riyadh, 11426, Saudi Arabia; yaseenarabi@yahoo.com; icul1@ngha.med.sa

Editors note: For the study protocol pertaining to this article, please see Appendix 2, available at www.cma.ca/cgi/content /full/cmaj.090707/DC1.